Cadonilimab Combined With Fruquintinib and SBRT as Athird-line and Posterior Line Treatment in Patients With MSS CRC

A Phase II Study to Assess the Efficacy and Safety of Cadonilimab Combined With Fruquintinib and SBRT as A third-line and Posterior Line Treatment in Patients With MSS Colorectal Cancer

Trial Details

NCT ID
NCT06168786
Phase
PHASE2
Sponsor
Huazhong University of Science and Technology
Status
RECRUITING
Cancer Type
Colorectal Cancer
Interventions
  • Fruquintinib
  • Cadonilimab
  • SBRT
Locations (sample)
  • Wuhan, Hubei, China|30.58333,114.26667

Key Eligibility Criteria

  • Provision of written Informed Consent Form (ICF) prior to any study specific procedures
  • Age ≥ 18 years, ≤75 years
  • Histologically or cytologically confirmed advanced Stage IV primary colorectal cancer
  • MSI status: MSS

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Colorectal Cancer Trials on Trialify →